JP2024537234A - 操作されたＴＧＦ－βモノマーおよび使用法 - Google Patents

操作されたＴＧＦ－βモノマーおよび使用法 Download PDF

Info

Publication number
JP2024537234A
JP2024537234A JP2024521130A JP2024521130A JP2024537234A JP 2024537234 A JP2024537234 A JP 2024537234A JP 2024521130 A JP2024521130 A JP 2024521130A JP 2024521130 A JP2024521130 A JP 2024521130A JP 2024537234 A JP2024537234 A JP 2024537234A
Authority
JP
Japan
Prior art keywords
tgf
seq
amino acid
monomer
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537234A5 (enExample
Inventor
アンドリュー ピー． ヒンク，
クリスティン デポー，
グレッグ エム． デルゴフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2024537234A publication Critical patent/JP2024537234A/ja
Publication of JP2024537234A5 publication Critical patent/JP2024537234A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024521130A 2021-10-11 2022-10-11 操作されたＴＧＦ－βモノマーおよび使用法 Pending JP2024537234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254249P 2021-10-11 2021-10-11
US63/254,249 2021-10-11
PCT/US2022/077879 WO2023064747A1 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Publications (2)

Publication Number Publication Date
JP2024537234A true JP2024537234A (ja) 2024-10-10
JP2024537234A5 JP2024537234A5 (enExample) 2025-10-10

Family

ID=85988028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521130A Pending JP2024537234A (ja) 2021-10-11 2022-10-11 操作されたＴＧＦ－βモノマーおよび使用法

Country Status (9)

Country Link
US (1) US20240425559A1 (enExample)
EP (1) EP4416172A4 (enExample)
JP (1) JP2024537234A (enExample)
KR (1) KR20240082356A (enExample)
CN (1) CN118103390A (enExample)
AU (1) AU2022367394B2 (enExample)
CA (1) CA3232809A1 (enExample)
TW (1) TW202330579A (enExample)
WO (1) WO2023064747A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US11091523B2 (en) * 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling
JP2023539195A (ja) * 2020-08-27 2023-09-13 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用

Also Published As

Publication number Publication date
AU2022367394B2 (en) 2026-03-19
KR20240082356A (ko) 2024-06-10
TW202330579A (zh) 2023-08-01
CN118103390A (zh) 2024-05-28
AU2022367394A1 (en) 2024-04-11
CA3232809A1 (en) 2023-04-20
WO2023064747A1 (en) 2023-04-20
EP4416172A4 (en) 2025-12-17
US20240425559A1 (en) 2024-12-26
EP4416172A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
KR101658247B1 (ko) 모듈 인식 도메인을 통한 항체 표적화
EP3528833B1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
EP2489360A1 (en) Stabilized MAML peptides and uses thereof
JP2017529059A5 (enExample)
JP6279788B2 (ja) 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP2020500511A (ja) 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用
CN108430511A (zh) 一种药物设计方法和获得的药物及其应用
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
US11033609B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
US12186376B2 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
CN112292402B (zh) 抗肿瘤融合蛋白及其制法和应用
AU2022367394B2 (en) Engineered tgf-beta monomers and methods of use
CN102993314B (zh) 一种抗肿瘤融合蛋白及其制备方法和用途
CN113908253A (zh) 环状鞘脂激活蛋白原肽及其用途
HK40109585A (zh) 工程化TGF- β单体及其使用方法
CN102470157B (zh) 广谱erbb配体结合分子及其制备和使用方法
WO2008120263A2 (en) Prokineticins receptors antagonists, derivatives and uses thereof
KR20150010957A (ko) 넓은 스펙트럼 erbb 리간드 결합 분자 및 그의 사용 방법
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
CN110520144A (zh) 肽激酶抑制剂及其使用方法
CA3219685A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
JP2025509985A (ja) 免疫原性細胞死適用のためのシステムおよび方法
CN106046170A (zh) 一种新型trail融合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251002